In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4261-4266

  Almeida, Deepak ^a   Nuermberger, Eric ^a   Tyagi, Sandeep ^a   Bishai, William R ^a   Grosset, Jacques ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Tuberculosis Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM MUTANT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; VALIDATION PROCESS;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; LUNG; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS;

EID: 36749021610     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01123-07     Document Type: Article

References (37)

1. Aubry, A., N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, and L. M. Fisher. 2006. Novel gyrase mutations in quinolone-resistant and -hypersus-ceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
2. Aziz, M. A., A. Wright, A. Laszlo, A. De Muynck, F. Portaels, A. Van Deun, C. Wells, P. Nunn, L. Blanc, and M. Raviglione. 2006. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368:2142-2154.
3. Bozeman, L., W. Burman, B. Metchock, L. Welch, and M. Weiner. 2005. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin. Infect. Dis. 40:386-391.
4. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
5. Canetti, G., S. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T. Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. W. H. O. 29:565-578.
6. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morb. Mortal. Wkly. Rep. 55:301-305.
7. Chan, E. D., V. Laurel, M. J. Strand, J. F. Chan, M. L. Huynh, M. Goble, and M. D. Iseman. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med 169:1103-1109.
8. Cheng, A. F. B., W. W. Yew, E. W. C. Chan, M. L. Chin, M. M. M. Hui, and R. C. Y. Chan. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601.
9. Dong, Y., X. Zhao, B. N. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44: 2581-2584.
10. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
11. Dye, C., M. Hosseini, and C. Watt. 2007. Did we reach the 2005 targets for tuberculosis control? Bull. W. H. O. 85:364-369.
12. Ginsburg, A. S., N. Hooper, N. Parrish, K. E. Dooley, S. E. Dorman, J. Booth, M. Diener-West, W. G. Merz, W. R. Bishai, and T. R. Sterling. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis. 37:1448-1452.
13. Ginsburg, A. S., R. Sun, H. Calamita, C. P. Scott, W. R. Bishai, and J. H. Grosset. 2005. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob. Agents Chemother. 49:3977-3979.
14. Ginsburg, A. S., S. C. Woolwine, N. Hooper, W. H. Benjamin, Jr., W. R. Bishai, S. E. Dorman, and T. R. Sterling. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med. 349:1977-1978.
15. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salftnger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
16. Iseman, M. D. 1994. Evolution of drug-resistant tuberculosis: a tale of two species. Proc. Natl. Acad. Sci. USA 91:2428-2429.
17. Johnson, J. L., D. J. Hadad, W. H. Boom, C. L. Daley, C. A. Peloquin, K. D. Eisenach, D. D. Jankus, S. M. Debanne, E. D. Charlebois, E. Maciel, M. Palaci, and R. Dietze. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10:605-612.
18. Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology. A guide for the level III laboratory. Centers for Disease Control and Prevention, Atlanta, GA.
19. Kocagöz, T., C. J. Hackbarth, I. Ünsal, E. Y. Rosenberg, H. Nikaido, and H. F. Chambers. 1996. Gyrase mutations in laboratory-selected, fiuoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774.
20. Lienhardt, C., R. Rustomjee, J. Allen, T. Mthigane, J. Levin, B. Fourie, G. Davies, J. Horton, T. Kanyok, and D. Mitchison. 2005. Comparison of 2-months sterilizing activities of several quinolone-containing regimens: preliminary results of a phase II trial in South Africa, abstr. LB2-13. Abstr. 45th Intense! Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
21. Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
22. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, W. Bishai, R., and J. Grosset. 2003. Assessment of moxifloxacin activity at clinically relevant dosages in the mouse model of tuberculosis. Am. J. Respir. Crit. Care Med. 169:A433. (Abstract.)
23. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426.
24. Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462.
25. Siddiqi, N., M. Shamim, S. Hussain, R. K. Choudhary, N. Ahmed, Prachee, S. Banerjee, G. R. Savithri, M. Alam, N. Pathak, A. Amin, M. Hanief, V. M. Katoch, S. K. Sharma, and S. E. Hasnain. 2002. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in north India. Antimicrob. Agents Chemother. 46:443-450.
26. Spigelman, M. K. 2007. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196:S28-S34.
27. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
28. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Krol, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797.
29. Tahaoglu, K., T. Torun, T. Sevim, G. Atac, A. Kir, L. Karasulu, I. Ozmen, and N. Kapakli. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174.
30. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
31. van Soolingen, D., P. W. M. Hermans, P. E. W. de Haas, D. R. Soll, and J. D. A. van Embden. 1991. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29:2578-2586.
32. Wise, R., J. M. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510.
33. Yew, W. W., C. K. Chan, C. H. Chau, C. M. Tam, C. C. Leung, P. C. Wong, and J. Lee. 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744-751.
34. Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother. 46:1875-1879.
35. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
36. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.
37. Zignol, M., M. S. Hosseini, A. Wright, C. L. Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.